SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 9th, 2017 • Biotime Inc • Biological products, (no disgnostic substances)
This Second Amended and Restated License Agreement (this “Second Amendment”) is made and entered into as of June 15, 2017 and will become effective as of the Date of the Second Amendment as defined below, as an amendment of the Research and License Agreement signed between the Parties on the Effective Date (the "Original Agreement"), as amended by the Amended and Restated Research and License Agreement signed on October 7, 2010 (the “First Amendment”) and the letter agreement of May 13, 2014 as supplemented by a letter agreement dated August 3, 2016 (the “Letter Agreement” and the Original Agreement, as amended by the First Amendment, the Letter Agreement and this Second Amendment, the "Agreement"), by and between: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., a company duly incorporated under the laws of Israel (“Hadasit”) and CELL CURE NEUROSCIENCES LTD., a company duly incorporated under the laws of Israel (the “Company”) (each a “Party” and jointly the “Parties”).
